Bavarian Nordic A/S (CPH:BAVA)
Denmark
· Delayed Price · Currency is DKK 174.20
+0.45 (0.26%)
Feb 21, 2025, 4:59 PM CET
Bavarian Nordic Company Description
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.
The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.
It is also developing MVA-BN for the treatment of smallpox. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally.
Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Bavarian Nordic A/S
| Country | Denmark |
| Founded | 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,379 |
| CEO | Paul Chaplin |
Contact Details
Address: Philip Heymans Alle 3 Hellerup, 2900 Denmark | |
| Phone | 45 33 26 83 83 |
| Website | bavarian-nordic.com |
Stock Details
| Ticker Symbol | BAVA |
| Exchange | Copenhagen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0015998017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul John Chaplin MSc, Ph.D. | Chief Executive Officer and President |
| Henrik Juuel M.Sc. | Chief Financial Officer and Executive Vice President |
| Russell Thirsk M.Sc. | Executive Vice President and Chief Operating Officer |
| Rolf Sass Sørensen | Vice President of Investor Relations and Communications |
| Anu Helena Kerns M.Sc. | Executive Vice President and Chief People and Sustainability Officer |
| Jean-Christophe May M.B.A., Pharm.D. | Executive Vice President and Chief Commercial Officer |